Latanoprost Noridem Enterprises (Latanoprost)

• Latanoprost belongs to the prostaglandin analog class and is used to manage conditions that require reduction of intraocular pressure.
• Open‑angle glaucoma: lowers intraocular pressure to prevent optic nerve damage.
• Ocular hypertension: reduces elevated eye pressure to lower the risk of developing glaucoma.
• Post‑surgical IOP control: helps maintain target pressure after glaucoma filtration surgery.

• Latanoprost is a prostaglandin F2α analog that binds to FP receptors in the ciliary body, enhancing uveoscleral outflow of aqueous humor. By increasing this unconventional drainage pathway, the drug effectively reduces intraocular pressure, helping to protect the optic nerve from pressure‑related damage.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects

• Eye redness or hyperemia
• Eye irritation or foreign‑body sensation
• Blurred vision
• Increased eyelash growth (hypertrichosis)
• Darkening of the iris (permanent pigment change)
• Mild ocular discomfort on instillation

Serious or Rare Side Effects

• Ocular inflammation (uveitis, iritis)
• Severe allergic reaction (contact dermatitis, swelling)
• Paradoxical increase in intraocular pressure
• Corneal edema or keratitis
• Vision loss or sudden visual disturbances

• Before prescribing Latanoprost, clinicians should consider several safety measures.
• Monitor intraocular pressure regularly: ensure therapeutic response and detect paradoxical rise.
• Assess for ocular infection or inflammation: avoid use in active conjunctivitis or keratitis.
• Use with caution in patients with known hypersensitivity to prostaglandin analogs.
• Pregnancy and lactation: safety data are limited; prescribe only if benefit outweighs risk.
• Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, requiring attention to dosing and monitoring.

Major Interactions (Avoid)

• Concomitant use with other prostaglandin analog eye drops: increased risk of ocular side effects.
• Simultaneous topical corticosteroids: may diminish IOP‑lowering efficacy.
• Combination with beta‑blocker eye drops: additive IOP reduction may require monitoring.

Moderate Interactions (Monitor Closely)

• Systemic non‑steroidal anti‑inflammatory drugs: may alter prostaglandin metabolism.
• Anticholinergic eye drops: could affect tear production and comfort.
• Other ocular hypotensive agents (e.g., carbonic anhydrase inhibitors): monitor IOP for synergistic effects.